Clinical Trials
6
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2013
Recruiting
6
100.0%
No approval data available
- Abivax SA agreed to repurchase all outstanding royalty certificates issued in 2022 for a total of $90 million, split evenly between cash and an equity offering of 403,347 American Depositary Shares. - The transaction eliminates a royalty overhang that had weighed on future commercialization economics for lead candidate obefazimod, currently in Phase 3 trials for ulcerative colitis. - The company's cash runway remains unchanged into Q4 2027, with €530.4 million in cash and equivalents reported as of December 31, 2025. - The equity component results in approximately 0.5% dilution for existing shareholders, with new ADSs priced at $111.57 per share based on a five-day volume-weighted average price.
- The FDA approved mirikizumab (Omvoh) and guselkumab (Tremfya) for moderately to severely active Crohn's disease in early 2025, expanding IL-23-targeted therapy options for inflammatory bowel disease patients. - Guselkumab demonstrated superiority over ustekinumab in multiple endoscopic endpoints in phase 3 GALAXI trials, while also receiving approval for a subcutaneous induction regimen for ulcerative colitis. - Fecal microbiota transplantation showed promise as a first-line treatment for primary C. difficile infection, achieving clinical cure rates of 66.7% compared to 61.2% with standard vancomycin therapy. - Novel therapies including icotrokinra for ulcerative colitis and EBX-102-02 for irritable bowel syndrome with constipation demonstrated positive results in phase 2 trials.
